Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review

AlMuhizi, Faisal; Vecillas, Leticia de las; Gilbert, Lucy; Copaescu, Ana; Isabwe, Ghislaine Annie Clarisse

doi:10.1007/s12016-022-08932-2

Cited by 16 publications

(25 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients in both groups received standard premedication regimens including corticosteroids and antihistamines. 7,20 Infusion tubing was primed with taxane and attached directly to the patient's intravenous access. A three-step titration was implemented on the basis of the patient's final, prescribed infusion rate, and steps were determined as follows: Step 1: 1% of the final, infusion rate (calculated on the basis of the patient's treatment plan) over 15 minutes; step 2: 10% of the infusion rate over 15 minutes; and step 3: 100% of the infusion rate until completion (Fig 1).…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures

Lynch

Menon

Mazzola

et al. 2023

JCO Oncology Practice

View full text Add to dashboard Cite

INTRODUCTION Patients receiving taxanes are at risk for developing hypersensitivity reactions (HSRs) primarily during first and second lifetime exposures. Immediate HSRs require emergency care and can interfere with the continuation of preferred treatment. Although different approaches to slow titration have been used successfully for desensitization after HSR occurrence, there are no standardized recommendations for taxane titration to prevent HSRs. PURPOSE To determine if a gradual, three-step infusion rate titration decreases the rate and severity of immediate HSRs during first and second lifetime exposures to paclitaxel and docetaxel. METHODS We used a prospective, interventional design with historical comparisons to evaluate a sample of 222 first and second lifetime exposure paclitaxel and docetaxel infusions. The intervention was a three-step infusion rate titration provided at the initiation of first and second lifetime exposures. Ninety-nine titrated infusions were compared with 123 historical records of nontitrated infusions. RESULTS Compared with the nontitrated group (n = 123), the titrated group (n = 99) had significantly less HSRs (19% v 7%; P = .017). No significant difference in HSR severity was found between groups ( P = 1.00). However, four nontitrated patients received epinephrine, and one required transfer to the emergency department (ED) because of reaction severity. In contrast, no titrated patients received epinephrine or required transfer to the ED. In the nontitrated group, seven patients did not complete their infusions versus one patient in the titrated group. CONCLUSION A standardized, three-step infusion rate titration prevented HSR occurrence. Significant issues affecting practice feasibility and sustainability were addressed.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures

Lynch

Menon

Mazzola

et al. 2023

JCO Oncology Practice

View full text Add to dashboard Cite

show abstract

“…The use of premedication in reactions to chemotherapy is still under discussion. A literature review regarding preventive premedication strategies in the prevention and management of hypersensitivity reactions to chemotherapy revealed that most premedication regimens including antihistamines, H2 antagonists, leukotriene receptor antagonists and corticosteroids have been derived empirically rather than determined through randomized trials [18 ▪▪ ]. Omalizumab, although not licensed as premedication or adjuvant therapy in chemotherapy desensitization protocols, revealed subservience as a premedication in RDD [19 ▪ ].…”

Section: Management Of Adverse Drug Reactionsmentioning

confidence: 99%

Management of adverse reactions induced by chemotherapy drugs

Abreu¹,

Cernadas

2022

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewThere is a broad spectrum of chemotherapy-induced adverse reactions. Hypersensitivity reactions are being extensively studied as they can affect the ideal treatment. The goal of this review is to describe the current management of adverse reactions to chemotherapy, focusing on hypersensitivity events. Recent findingsThe range of possible desensitization protocols is increasing, as well as the delabeling algorithms and diagnostic tools. One-bag desensitization protocols, omalizumab use in immediate hypersensitivity reactions, slow desensitization protocols in nonimmediate hypersensitivity reactions and standardization of skin tests for platinum drugs, are some examples.

show abstract

“…3, il est conseillé de ne pas réintroduire le traitement. L'incidence des réactions d'hypersensibilité diffère en fonction des drogues de chimiothérapie et une prémédication à base de corticoïdes et d'anti-H1/H2 peut être instaurée avant chaque cure [41]. En cas de récidive malgré la prémédication, on peut, en fonction du type de drogue (taxanes, oxaliplatine), du profil du patient et des impératifs de la prise en charge oncologique, discuter d'un protocole de désensibilisation en centre expert [42,43].…”

Section: Fluoropyrimidinesunclassified

Prise en charge des complications des chimiothérapies : ce qu’il faut connaître

2022

Hépato-Gastro &Amp; Oncologie Digestive

View full text Add to dashboard Cite

Les chimiothérapies ont de nombreuses toxicités, notamment digestives. Leur prise en charge doit être rigoureuse, basée sur les recommandations de référence, car elles ont potentiellement un impact pronostique péjoratif. Cet article fait le point sur les données pratiques récentes de la prise en charge des toxicités digestives (nausées/vomissements, diarrhée, constipation, mucite), hématologiques (anémie, thrombopénie, neutropénie, neutropénie avec fièvre), cardiaques (fluoropyrimidines, oxaliplatine) et des réactions infusionnelles des chimiothérapies, en oncologie digestive.

show abstract

Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review

Cited by 16 publications

References 82 publications

A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures

A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures

Management of adverse reactions induced by chemotherapy drugs

Prise en charge des complications des chimiothérapies : ce qu’il faut connaître

Contact Info

Product

Resources

About